BR112022010335A2 - Composição sólida oral de óleo canabinoide para o tratamento de distúrbios gastrointestinais - Google Patents
Composição sólida oral de óleo canabinoide para o tratamento de distúrbios gastrointestinaisInfo
- Publication number
- BR112022010335A2 BR112022010335A2 BR112022010335A BR112022010335A BR112022010335A2 BR 112022010335 A2 BR112022010335 A2 BR 112022010335A2 BR 112022010335 A BR112022010335 A BR 112022010335A BR 112022010335 A BR112022010335 A BR 112022010335A BR 112022010335 A2 BR112022010335 A2 BR 112022010335A2
- Authority
- BR
- Brazil
- Prior art keywords
- oil
- gastrointestinal disorders
- canabinoid
- treatment
- solid composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958392P | 2020-01-08 | 2020-01-08 | |
| PCT/EP2021/050245 WO2021140183A1 (en) | 2020-01-08 | 2021-01-08 | Oral solid cannabinoid oil composition for treating gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010335A2 true BR112022010335A2 (pt) | 2022-08-16 |
Family
ID=74236138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010335A BR112022010335A2 (pt) | 2020-01-08 | 2021-01-08 | Composição sólida oral de óleo canabinoide para o tratamento de distúrbios gastrointestinais |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12186281B2 (https=) |
| EP (1) | EP4087547A1 (https=) |
| JP (1) | JP2023509675A (https=) |
| CN (1) | CN114845705A (https=) |
| AU (1) | AU2021206021A1 (https=) |
| BR (1) | BR112022010335A2 (https=) |
| CA (1) | CA3164489A1 (https=) |
| WO (1) | WO2021140183A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021417405A1 (en) * | 2021-01-08 | 2023-06-22 | Société des Produits Nestlé S.A. | Oral solid cannabinoid oil composition for treating central nervous system disorders |
| WO2023092079A1 (en) * | 2021-11-19 | 2023-05-25 | Bryant Cynthia W | Use of cannabinoid compounds to treat gastrointestinal disorders |
| GB2618322A (en) * | 2022-04-29 | 2023-11-08 | 113 Botanicals Ltd | Compositions and methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120231083A1 (en) * | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
| US8808736B2 (en) * | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
| WO2012109216A1 (en) * | 2011-02-11 | 2012-08-16 | Zx Pharma, Llc | Multiparticulate l-menthol formulations and related methods |
| US8758826B2 (en) * | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| CA2909591C (en) * | 2013-04-23 | 2017-03-28 | Zx Pharma, Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
| AU2017216928B2 (en) | 2016-02-11 | 2018-09-20 | Gelpell Ag | Oral solid cannabinoid formulations, methods for producing and using thereof |
| US20190091198A1 (en) * | 2016-03-28 | 2019-03-28 | Lihi BAR-LEV SCHLEIDER | Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract |
| WO2017193072A1 (en) | 2016-05-06 | 2017-11-09 | Harvest Direct Enterprises Llc | The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals |
| MX382609B (es) * | 2016-07-25 | 2025-03-13 | Canopy Growth Corp | Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. |
| CA3036585A1 (en) | 2016-09-27 | 2018-04-05 | CannTab Therapeutics Limited | Sustained release cannabinoid formulations |
| US20200163931A1 (en) | 2016-10-12 | 2020-05-28 | Columbia Care Llc | Oral composition of extracted cannabinoids and methods of use thereof |
| CN108853079A (zh) * | 2017-05-15 | 2018-11-23 | 汉义生物科技（北京）有限公司 | 大麻素类化合物在治疗肠易激综合征中的应用 |
| CA3078549A1 (en) * | 2017-10-05 | 2019-04-11 | Receptor Holdings, Inc. | Rapid onset and extended action plant-based and synthetic cannabinoid formulations |
| WO2019082171A1 (en) * | 2017-10-27 | 2019-05-02 | Alvit Pharma | ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY |
| WO2019234743A1 (en) | 2018-06-06 | 2019-12-12 | Icdpharma Ltd. | Anti-inflammatory synergistic compositions comprising cannabinoids and licorice |
| GB2584341B (en) * | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
-
2021
- 2021-01-08 EP EP21700003.3A patent/EP4087547A1/en active Pending
- 2021-01-08 JP JP2022540709A patent/JP2023509675A/ja active Pending
- 2021-01-08 AU AU2021206021A patent/AU2021206021A1/en active Pending
- 2021-01-08 CN CN202180007577.3A patent/CN114845705A/zh active Pending
- 2021-01-08 WO PCT/EP2021/050245 patent/WO2021140183A1/en not_active Ceased
- 2021-01-08 BR BR112022010335A patent/BR112022010335A2/pt unknown
- 2021-01-08 US US17/758,315 patent/US12186281B2/en active Active
- 2021-01-08 US US17/144,784 patent/US11717494B2/en active Active
- 2021-01-08 CA CA3164489A patent/CA3164489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210205235A1 (en) | 2021-07-08 |
| US12186281B2 (en) | 2025-01-07 |
| US11717494B2 (en) | 2023-08-08 |
| JP2023509675A (ja) | 2023-03-09 |
| WO2021140183A1 (en) | 2021-07-15 |
| CA3164489A1 (en) | 2021-07-15 |
| US20230065736A1 (en) | 2023-03-02 |
| CN114845705A (zh) | 2022-08-02 |
| AU2021206021A1 (en) | 2022-06-02 |
| EP4087547A1 (en) | 2022-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010335A2 (pt) | Composição sólida oral de óleo canabinoide para o tratamento de distúrbios gastrointestinais | |
| EP3924481A4 (en) | Compositions and methods for treating hemoglobinopathies | |
| BRPI0915536A2 (pt) | salicilatos acetilados de ácidos graxos e seus usos | |
| CL2021003180A1 (es) | Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico (divisional de solicitud n° 00723-2021) | |
| BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
| BRPI0810555B8 (pt) | implante dentário | |
| MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
| BR112021024255A2 (pt) | Kits compreendendo composições para tratamento bucal de dose unitária | |
| CO2021008816A2 (es) | Moduladores de trex1 | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| BR112018007958A2 (pt) | composições e métodos que usam um polifenol para a saúde musculoesquelética | |
| BR112015006499A2 (pt) | composição de óleo de horlelã-pimenta de liberação controlada microparticulada com revestimento entérico e métodos relacionados | |
| GT201300096A (es) | Composiciones farmaceuticas que contienen un inhibidor de dgat1 | |
| BR112018000786A2 (pt) | métodos e composições usando bifidobacterium longum para modular a reatividade emocional e tratar ou evitar perturbações subclínicas do estado de humor | |
| BR112015019264A8 (pt) | cápsulas para o tratamento de helicobacter pylori e seu uso". | |
| BR112019024845A2 (pt) | composições e métodos para regular cascatas hormonais em transtornos de estresse | |
| EP2496251A4 (en) | METHOD, COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY DISEASES | |
| BR112022002122A2 (pt) | Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo | |
| BR122021012549B8 (pt) | Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| BR112015008038A2 (pt) | gomas de mascar | |
| EP4232075A4 (en) | Compounds,compositions and methods of use to treat spinal fusions | |
| BR112013033438A2 (pt) | dha e epa na redução do estresse oxidativo | |
| CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
| MX2024002062A (es) | Composicion que comprende akkermansia pasteurizada para el tratamiento o la prevencion de la ansiedad relacionada con el sii. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |